Primary Hypofractionated Radiation Therapy for Localized Prostate Cancer: A Systematic Review

https://effectivehealthcare.ahrq.gov/products/hypofractionated-radiation-therapy/draft-report Primary Hypofractionated Radiation Therapy for Localized Prostate Cancer (Available for comment until August 29, 2025) The objective of this review is to evaluate, in adults with localized prostate cancer receiving primary external beam radiation therapy (EBRT), the comparative benefits and harms of (1) moderate hypofractionation (MHF; 2.4-3.4 Gy/fraction) vs. conventional fractionation (CF; 1.8 to 2.0 Gy/fraction), (2) ultrahypofractionation (UHF; ≥5.0 Gy/fraction) vs. MHF or CF, (3) different dose schedules, (4) varying target volumes, and (5) alternative treatment-planning and delivery techniques.